Abstract: The present subject matter relates to novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one represented by Formula II: , pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV, V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2 -hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms.

Abstract: The present invention relates to novel compounds of formula (I) and to the salts, solvates and prodrugs thereof, wherein the meanings of the various substituents are as disclosed in the description. Said compounds are useful for the treatment or prevention of psoriasis and other immune diseases.

Abstract: New phosphoramide derivatives of formula (I) and the salts and solvates thereof, wherein the meanings of the various substituents are as disclosed in the description. Said compounds are useful as antiinflammatory and analgesic agents.

Abstract: Process for the preparation of pyrimidone derivatives of formula I, which comprises reacting a compound of formula II with a compound of formula III in the presence of a base. The pyrimidone derivatives of formula I are useful as antifungal agents.

Abstract: Process for the preparation of pyrimidone derivatives of formula I, which comprises reacting a compound of formula II with a compound of formula III in the presence of a base. The pyrimidone derivatives of formula I are useful as antifungal agents.

Abstract: Compounds of general formula I and their salts and solvates are antifungal agents and as such are useful in the treatment of various fungal infections. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: Compounds of general formula I and their salts and solvates are antifungal agents and as such are useful in the treatment of various fungal infections. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(.dbd.O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formmula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH,--OR.sub.7, --OC(.dbd.O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(.dbd.O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(.dbd.O)--, R.sub.2 is optionally substituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally substituted phenyl.

Abstract: Compounds of formula I and their salts and solvates are useful for the treatment or prevention of inflammatory bowel disease. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: Compounds of general formula I and their salts and solvates are PAF antagonists and as such are useful in the treatment of various diseases or disorders mediated by PAF. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(.dbd.O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH, --OR.sub.7, --OC(.dbd.O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(.dbd.O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(.dbd.O)--, R.sub.2 is optionally susbtituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally susbtituted phenyl.

Abstract: The present invention relates to new imidazopyridine derivatives of formula I ##STR1## wherein: one of A, B, C and D is N and the other are CR, wherein each R independently represents hydrogen, C.sub.1-4 alkyl, COOH or halogen; R.sub.1 represents C.sub.1-4 alkyl or C.sub.3-7 cycloalkyl; Ar.sub.1 represents phenyl or pyridyl which can be optionally substituted; V represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, aryl, aryl-(C.sub.1-4)alkyl or a 5- or 6-membered aromatic heterocycle; the group X-Y represents C.dbd.C or CH--CR.sub.3 ; R.sub.3 represents hydrogen, C.sub.1-4 alkyl or aryl-(C.sub.1-4)alkyl; Z represents among others --CO.sub.2 R.sub.4, --tetrazol-5-yl, --CONHSO.sub.2 R.sub.4, --CONR.sub.4 R.sub.5,--CH.sub.2 NHSO.sub.2 R.sub.4 ; R.sub.4 and R.sub.5 independently represent hydrogen, C.sub.1-4 alkyl, aryl, aryl-(C.sub.1-4)alkyl or perfluoro-(C.sub.1-4)alkyl; W represents hydrogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.3-7 cycloalkyl, aryl, aryl-(C.sub.1-4)alkyl, C.sub.

Abstract: The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(=O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH, --OR.sub.7, --OC(=O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(=O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(=O)--, R.sub.2 is optionally susbtituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally susbtituted phenyl.

Abstract: The present invention relates to 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine, to a process for its preparation and to pharmaceutical compositions containing it. This compound is a dual PAF antagonist and antihistamine.

Abstract: The present invention relates to new cyanomethylpyridine dervatives of formula I ##STR1## wherein Y represents N or CH; R.sub.1 represents hydrogen, fluoro, chloro, difluoro or dichloro; R.sub.2 represents hydrogen or C.sub.1-4 alkyl; n is 0 or 1; p is 0 or 1; A represents a covalent bond or a group of formula --CONHCH(Ar)--, --NHCH(Ar)--, --SO.sub.2 NHCH(Ar)--, --NHCONHCH(Ar)-- or --OCONHCH(Ar)--, and when p is 1, A can also represent --CH(Ar)NH--; and Ar represents phenyl or phenyl substituted with halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trifluoromethyl. These compounds are PAF antagonist and/or 5-lipoxygenase inhibitors.

Abstract: The present invention relates to 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine, to a process for its preparation and to pharmaceutical compositions containing it. This compound is a dual PAF antagonist and antihistamine.

Abstract: The present invention relates to new sulfonamides having the formula I: ##STR1## wherein: R.sup.1 represents an alkyl, aryl or heteroaryl group; R.sup.2 is hydrogen or an alkyl, aryl or heteroaryl group; or R.sup.1 and R.sup.2 may form a ring; R.sup.3 is hydrogen or may form an oxazolidine ring together with R.sup.2, and this ring may be optionally substituted by one or two alkyl, aryl or heteroaryl groups at the postion 2; R.sup.7 is hydrogen or alkyl; X is CH or N; Ar is a phenyl ring or a substituted phenyl ring. The invention also relates to a procedure for their preparation and to pharmaceutical and agrochemical compositions containing them. These compounds are antifungal agents.

Abstract: The present invention relates to new tetralones having formula I: ##STR1## wherein R.sup.1 to R.sup.7 are as defined in claim 1. The invention also relates to processes for their preparation, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments. These compounds are antihypertensive and bronchodilator agents.